These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33088636)

  • 1. Fulminant type 1 diabetes: 20 years of discovery and development.
    Hanafusa T
    Diabetol Int; 2020 Oct; 11(4):310-314. PubMed ID: 33088636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re-Enlightenment of Fulminant Type 1 Diabetes under the COVID-19 Pandemic.
    Sano H; Imagawa A
    Biology (Basel); 2022 Nov; 11(11):. PubMed ID: 36421377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fulminant type 1 diabetes: Focusing on triggering factors.
    Qiu J; Yin W; Wang R; Luo S; Zhou Z
    Diabetes Metab Res Rev; 2024 Feb; 40(2):e3731. PubMed ID: 37814918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent findings on fulminant type 1 diabetes.
    Liu L; Zeng L; Sang D; Lu Z; Shen J
    Diabetes Metab Res Rev; 2018 Jan; 34(1):. PubMed ID: 28817230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological Aspects of Fulminant Type 1 Diabetes in Chinese.
    Wang Z; Zheng Y; Tu Y; Dai Z; Lin J; Zhou Z
    J Immunol Res; 2016; 2016():1858202. PubMed ID: 26981545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible involvement of autoimmunity in fulminant type 1 diabetes.
    Oikawa Y; Shimada A
    Diabetol Int; 2020 Oct; 11(4):329-335. PubMed ID: 33088639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fulminant index: A method of rapidly differentiating fulminant type 1 diabetes from diabetic ketoacidosis.
    Qiu J; Li X; Chen W; Ma X; Xie Z; Huang G; Luo S; Zhou Z
    Diabetes Metab Res Rev; 2022 Mar; 38(3):e3501. PubMed ID: 34614535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab-induced fulminant type 1 diabetes with C-peptide persistence at first referral.
    Kusuki K; Suzuki S; Mizuno Y
    Endocrinol Diabetes Metab Case Rep; 2020 Apr; 2020():. PubMed ID: 32478673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fulminant type 1 diabetes developed after influenza split vaccination.
    Sawamura T; Karashima S; Ohmori A; Sawada K; Aono D; Kometani M; Takeda Y; Yoneda T
    Endocrinol Diabetes Metab Case Rep; 2023 May; 2023(2):. PubMed ID: 37140990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case of new-onset fulminant type 1 diabetes mellitus accompanied by autoimmune thyroid disease after SARS-CoV-2 infection.
    Murakawa K; Aasi H; Sato K; Yoshioka S; Sho H; Inui R; Kosugi M; Hazama Y; Yasuda T
    Diabetol Int; 2024 Jul; 15(3):621-626. PubMed ID: 39101178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological changes in the pancreas of fulminant type 1 diabetes and slowly progressive insulin-dependent diabetes mellitus (SPIDDM): innate immunity in fulminant type 1 diabetes and SPIDDM.
    Kobayashi T; Nishida Y; Tanaka S; Aida K
    Diabetes Metab Res Rev; 2011 Nov; 27(8):965-70. PubMed ID: 22069294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fulminant type 1 diabetes: A comprehensive review of an autoimmune condition.
    Luo S; Ma X; Li X; Xie Z; Zhou Z
    Diabetes Metab Res Rev; 2020 Sep; 36(6):e3317. PubMed ID: 32223049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case report of fulminant type 1 diabetes mellitus associated with drug-induced hypersensitivity syndrome in an elderly patient with coxsackie B4 virus infection and human leukocyte antigen-A24 haplotype.
    Takeno A; Kanazawa I; Morita M; Takedani K; Miyake H; Yamamoto M; Nogami K; Kaneko S; Sugimoto T
    Endocr J; 2018 Jan; 65(1):129-132. PubMed ID: 28966225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Case of Fulminant Type 1 Diabetes with Gastric and Urinary Retention.
    Xing C; Zhao W; Wang Y
    Diabetes Ther; 2019 Feb; 10(1):291-298. PubMed ID: 30460498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and prognosis of fulminant type 1 diabetes mellitus in The Middle East: a comparative analysis in a 5-year nationwide cohort.
    Ata F; Khan AA; Khamees I; AlKodmani S; Al-Sadi A; Yaseen KB; Muthanna B; Godwin A; Beer SF; Bashir M
    BMC Endocr Disord; 2024 Mar; 24(1):33. PubMed ID: 38462602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High frequency of HLA B62 in fulminant type 1 diabetes with the drug-induced hypersensitivity syndrome.
    Onuma H; Tohyama M; Imagawa A; Hanafusa T; Kobayashi T; Kano Y; Ohashi J; Hashimoto K; Osawa H; Makino H; ;
    J Clin Endocrinol Metab; 2012 Dec; 97(12):E2277-81. PubMed ID: 23071161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fulminant type 1 diabetes mellitus].
    Imagawa A; Hanafusa T
    Rinsho Byori; 2010 Mar; 58(3):216-24. PubMed ID: 20408439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group.
    Imagawa A; Hanafusa T; Miyagawa J; Matsuzawa Y
    N Engl J Med; 2000 Feb; 342(5):301-7. PubMed ID: 10655528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulminant type I diabetes: the first case report in Thailand.
    Napartivaumnuay N; Suthornthepvarakul T; Deerochanawong C; Sarinnapakorn V; Niramitmahapanya S
    J Med Assoc Thai; 2013 Mar; 96 Suppl 3():S114-7. PubMed ID: 23682534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes.
    Haseda F; Imagawa A; Nishikawa H; Mitsui S; Tsutsumi C; Fujisawa R; Sano H; Murase-Mishiba Y; Terasaki J; Sakaguchi S; Hanafusa T
    PLoS One; 2016; 11(8):e0160576. PubMed ID: 27513516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.